Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors at an advisory committee meeting. | On second thought, the FDA figures it ...

Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...

For most investors, generating consistent income alongside capital appreciation is a common goal. For those seeking a blend ...

Moderna's bird flu vaccine development, supported by a U.S. government grant, could be a game changer if the bird flu spreads ...

Abbvie said on Friday it will record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...

A Canadian teen's breasts grew fourfold after receiving the Pfizer COVID-19 vaccine, raising concerns about a rare condition ...